Chemours Company (The) (NYSE:CC) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Chemours Company is involved in chemical business. It operating segment consists of Titanium Technologies, Fluoroproducts and Chemical Solutions. Titanium Technologies segment produces titanium dioxide and premium white pigment. Fluoroproducts segment provides fluoroproducts, refrigerants and industrial fluoropolymer resins. Chemical Solutions segment provides industrial and specialty chemicals. The company’s brand consists of Teflon(R), Ti-Pure(R), Krytox(R) Viton(R), Opteon(R) and Nafion(R). Chemours Company is headquartered in Wilmington. “

Other equities research analysts have also issued research reports about the company. Argus restated a “buy” rating and set a $55.00 price objective (up previously from $50.00) on shares of Chemours Company (The) in a research note on Thursday, August 10th. Jefferies Group LLC restated a “buy” rating and set a $48.00 price objective on shares of Chemours Company (The) in a research note on Friday, June 16th. ValuEngine upgraded Chemours Company (The) from a “hold” rating to a “buy” rating in a research note on Friday, June 2nd. Citigroup Inc. raised their price objective on Chemours Company (The) from $45.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, August 4th. Finally, BidaskClub upgraded Chemours Company (The) from a “hold” rating to a “buy” rating in a research note on Wednesday, July 12th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $51.50.

Shares of Chemours Company (CC) opened at 49.17 on Tuesday. Chemours Company has a 52 week low of $12.86 and a 52 week high of $51.59. The firm has a 50-day moving average price of $50.24 and a 200-day moving average price of $38.60. The stock has a market cap of $9.09 billion, a PE ratio of 32.18 and a beta of 3.64.

Chemours Company (The) (NYSE:CC) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.02. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter last year, the firm earned $0.27 EPS. Chemours Company (The)’s quarterly revenue was up 14.8% on a year-over-year basis. On average, analysts forecast that Chemours Company will post $3.51 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Chemours Company (The) (CC) Stock Rating Lowered by Zacks Investment Research” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/14/chemours-company-the-cc-stock-rating-lowered-by-zacks-investment-research.html.

In other news, VP Amy Trojanowski sold 2,500 shares of Chemours Company (The) stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $46.03, for a total value of $115,075.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider E Bryan Snell sold 10,000 shares of Chemours Company (The) stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $46.24, for a total value of $462,400.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,837 shares of company stock valued at $1,865,603. Insiders own 1.14% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Financial Architects Inc grew its position in shares of Chemours Company (The) by 1,230.3% in the 2nd quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock worth $111,000 after acquiring an additional 2,719 shares in the last quarter. Acrospire Investment Management LLC lifted its holdings in shares of Chemours Company (The) by 3.4% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,076 shares of the specialty chemicals company’s stock worth $117,000 after purchasing an additional 100 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Chemours Company (The) by 2,138.8% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock worth $118,000 after purchasing an additional 2,973 shares during the last quarter. Schroder Investment Management Group bought a new stake in shares of Chemours Company (The) in the 1st quarter worth approximately $156,000. Finally, Smithfield Trust Co. lifted its holdings in shares of Chemours Company (The) by 521.4% in the 2nd quarter. Smithfield Trust Co. now owns 4,791 shares of the specialty chemicals company’s stock worth $182,000 after purchasing an additional 4,020 shares during the last quarter. Institutional investors own 72.90% of the company’s stock.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.